MDT

98.64

+1.99%↑

A

135.65

-2.83%↓

VEEV

215.94

-2.8%↓

HQY

83.67

-1.59%↓

NEOG

9.34

+1.19%↑

MDT

98.64

+1.99%↑

A

135.65

-2.83%↓

VEEV

215.94

-2.8%↓

HQY

83.67

-1.59%↓

NEOG

9.34

+1.19%↑

MDT

98.64

+1.99%↑

A

135.65

-2.83%↓

VEEV

215.94

-2.8%↓

HQY

83.67

-1.59%↓

NEOG

9.34

+1.19%↑

MDT

98.64

+1.99%↑

A

135.65

-2.83%↓

VEEV

215.94

-2.8%↓

HQY

83.67

-1.59%↓

NEOG

9.34

+1.19%↑

MDT

98.64

+1.99%↑

A

135.65

-2.83%↓

VEEV

215.94

-2.8%↓

HQY

83.67

-1.59%↓

NEOG

9.34

+1.19%↑

Search

Twist Bioscience Corp

Cerrado

SectorSalud

41.38 -0.02

Resumen

Variación precio

24h

Actual

Mínimo

39.05

Máximo

42.44

Métricas clave

By Trading Economics

Ingresos

-48M

-27M

Ventas

3M

99M

Margen de beneficio

-27.41

Empleados

979

EBITDA

3.2M

-21M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 meses

-0.39% downside

Dividendos

By Dow Jones

Próximas Ganancias

2 feb 2026

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

669M

2.5B

Apertura anterior

41.4

Cierre anterior

41.38

Noticias sobre sentimiento de mercado

By Acuity

50%

50%

159 / 361 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

Twist Bioscience Corp Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

20 ene 2026, 23:43 UTC

Charlas de Mercado

Gold Consolidates; May Face Technical Correction -- Market Talk

20 ene 2026, 23:42 UTC

Charlas de Mercado

Nikkei May Fall Amid Concerns Over U.S.-Europe Trade Relations -- Market Talk

20 ene 2026, 23:41 UTC

Ganancias

Netflix Revenue and Profit Rise as Subscriptions Top 325 Million -- 2nd Update

20 ene 2026, 23:29 UTC

Charlas de Mercado

RBA Rate Hike in February Would Be a Painful One -- Market Talk

20 ene 2026, 23:26 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

20 ene 2026, 23:26 UTC

Charlas de Mercado

James Hardie Appeals More as Reece's U.S. Strategy Comes Under Scrutiny -- Market Talk

20 ene 2026, 22:45 UTC

Adquisiciones, fusiones, absorciones

ACCC: Ampol-EG Deal Is First Assessment Subject to Phase 2 Review Under New Merger Control Regime

20 ene 2026, 22:45 UTC

Adquisiciones, fusiones, absorciones

ACCC Seeks Submissions in Response to Phase 2 Notice by February 4

20 ene 2026, 22:44 UTC

Adquisiciones, fusiones, absorciones

ACCC: Ampol's Offer to Sell 19 Retail Fuel Sites Doesn't Adequately Address Issues

20 ene 2026, 22:44 UTC

Adquisiciones, fusiones, absorciones

ACCC Identifies 115 EG Sites Where Deal Could Substantially Lessen Competition

20 ene 2026, 22:43 UTC

Adquisiciones, fusiones, absorciones

ACCC Says Deal Could Substantially Lessen Competition in Retail Supply of Petrol, Diesel in Several Markets in Australia

20 ene 2026, 22:43 UTC

Adquisiciones, fusiones, absorciones

Ampol's Acquisition of EG Australia to Undergo In-Depth Review by Competition Regulator

20 ene 2026, 22:27 UTC

Adquisiciones, fusiones, absorciones

Netflix Plans to Roll Out New Mobile User Interface Later This Year, Co-CEO Says

20 ene 2026, 22:25 UTC

Adquisiciones, fusiones, absorciones

Netflix Co-CEO Sees Uptick in Engagement for TV-Based Games

20 ene 2026, 22:21 UTC

Adquisiciones, fusiones, absorciones

Netflix Would Keep 45-Day Theater Release Window for Warner Bros. Films, Co-CEO Says

20 ene 2026, 22:20 UTC

Adquisiciones, fusiones, absorciones

Netflix Excited to Strengthen Warner Bros.'s Theatrical-Distribution Business, Co-CEO Says

20 ene 2026, 22:19 UTC

Adquisiciones, fusiones, absorciones

Netflix Pleased With Early Results for Podcasts, Co-CEO Says

20 ene 2026, 22:18 UTC

Ganancias

Netflix Stock Is Falling. This Is Overshadowing the Streamer's Earnings Beat. -- Barrons.com

20 ene 2026, 22:17 UTC

Adquisiciones, fusiones, absorciones

Netflix's Live Events Are Boosting Retention, Co-CEO Says

20 ene 2026, 22:16 UTC

Adquisiciones, fusiones, absorciones

Netflix Remains 'Very Excited' About Live-Events Offering, Co-CEO Says

20 ene 2026, 22:15 UTC

Adquisiciones, fusiones, absorciones

Netflix's Proposed Deal for Warner Bros. Would Protect, Create Jobs, Co-CEO Says

20 ene 2026, 22:15 UTC

Adquisiciones, fusiones, absorciones

Netflix Competes for Attention Across Streaming, Broadcast, Cable, Gaming, Social Media, Video Platforms, Co-CEO Says

20 ene 2026, 22:13 UTC

Adquisiciones, fusiones, absorciones

Netflix Co-CEO: TV Landscape Has Never Been More Competitive

20 ene 2026, 22:11 UTC

Adquisiciones, fusiones, absorciones

Netflix Confident Warner Bros. Deal Would Pass Regulatory Review, Co-CEO Says

20 ene 2026, 22:10 UTC

Adquisiciones, fusiones, absorciones

Netflix Would Leverage Global Footprint, Streaming Expertise to Improve Warner Bros.'s HBO Max Service, Co-CEO Says

20 ene 2026, 22:08 UTC

Adquisiciones, fusiones, absorciones

Netflix Won't Raise Prices During Regulatory-Review Process for Pending Warner Bros. Deal, Co-CEO Says

20 ene 2026, 22:07 UTC

Adquisiciones, fusiones, absorciones

Netflix Sees Warner Bros. as Another Mechanism to Improve Offerings, Co-CEO Says

20 ene 2026, 22:06 UTC

Ganancias

Netflix Revenue and Profit Rise as Subscriptions Top 325 Million -- Update

20 ene 2026, 22:00 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

ESG Roundup: Market Talk

20 ene 2026, 21:50 UTC

Charlas de Mercado
Ganancias

Tech, Media & Telecom Roundup: Market Talk

Comparación entre iguales

Cambio de precio

Twist Bioscience Corp Esperado

Precio Objetivo

By TipRanks

-0.39% caída

Estimación a 12 meses

Media 41.25 USD  -0.39%

Máximo 43 USD

Mínimo 39 USD

De acuerdo con 5 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Twist Bioscience Corp Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

5 ratings

5

Comprar

0

Mantener

0

Vender

Puntuación técnica

By Trading Central

31.56 / 38.6884Soporte y Resistencia

Corto Plazo

Very Strong Bearish Evidence

Medio plazo

Bearish Evidence

Largo Plazo

Bearish Evidence

Sentimiento

By Acuity

159 / 361 Clasificación en Salud

Noticias sobre sentimiento de mercado

Neutral

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Twist Bioscience Corp

Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, it offers synthetic SARS-CoV-2 RNA reference sequences as positive controls to develop both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company has a strategic collaboration with bitBiome Inc. The company was incorporated in 2013 and is headquartered in South San Francisco, California.
help-icon Live chat